Loading financial data...

Day One Biopharmaceuticals, Inc. (DAWN) Financial Statements | Global Financial Data

Day One Biopharmaceuticals, Inc.

DAWNSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1845337

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$0.00	$0.00	—	—	—
Research and Development Expense	$130.5M	$85.6M	$43.6M	$9.1M	$13.9M
Operating Expenses	$206.1M	$146.9M	$72.7M	$13.8M	$14.9M
Operating Income (Loss)	-$206.1M	-$146.9M	-$72.7M	-$13.8M	-$14.9M
Nonoperating Income (Expense)	$17.1M	$4.7M	—	—	—
Income Tax Expense (Benefit)	$0.00	$0.00	—	—	—
Net Income (Loss) Attributable to Parent	-$188.9M	-$142.2M	—	-$40.5M	-$12.6M
Earnings Per Share, Basic

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$582.8M	$376.0M	$349.1M	$289.8M	$45.7M
Assets, Current	$562.3M	$375.3M	$347.9M	$289.4M	$45.1M
Cash and Cash Equivalents, at Carrying Value	$125.0M	$230.8M	$85.3M	$284.3M	$942.0K
Inventory, Net	$3.3M	$0.00	—	—	—
Liabilities	$80.0M	$29.5M	$17.0M	$8.7M	$2.2M
Liabilities, Current	$73.5M	$29.5M	$16.6M	$8.7M	$2.0M
Accounts Payable, Current	$3.3M	$2.6M	$260.0K	$1.7M	$202.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$146.9M	-$109.9M	-$48.5M	-$13.5M	-$4.5M
Net Cash Provided by (Used in) Investing Activities	$128.4M	-$255.1M	-$8.0M	-$92.0K	$0.00
Net Cash Provided by (Used in) Financing Activities	$164.0M	$165.9M	$297.1M	$30.0M	$30.9M
Payments to Acquire Property, Plant, and Equipment	$224.0K	$26.0K	$0.00	$92.0K	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)